A Phase I Study of LX-039 Tablets

NCT04097756 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: LX-039 tablets

Sponsor

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.